Hutch News
Results per Page:
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
January 20, 2020
Does CAR T-cell therapy leave patients vulnerable to infection?
$3.3M Cancer Moonshot grant to study how immunotherapy impacts patients’ ability to fight off bugs
Hutch influenza experts assay the latest science
Flu shots remain your best bet for protection, but no guarantee against infection
Dr. M. Elizabeth ‘Betz’ Halloran elected to National Academy of Medicine
Statistician honored for helping the world anticipate, manage and prevent infectious disease outbreaks
Life Sciences Research Foundation funds study to track evolution, spread of bird flu
Computational biologist and virologist Dr. Louise Moncla receives 3-year grant
Scientists gather in Seattle to share strategies for an HIV cure
Workshop focuses on ways to lower cost, broaden reach of gene therapy
Infections in immune-compromised patients: 5 new frontiers
Infectious disease experts gather in Seattle to find solutions for patients with compromised immunity
First systematic study of infections after CAR T-cell therapy
“Benchmark” research could help reduce complications of emerging immunotherapy
Good News: Drs. Grzelak, Anderson get Komen awards; Infectious Disease Sciences earns training grant; Drs. Bloom, Matsen named HHMI-Simons Faculty Scholars
Celebrating faculty and staff achievements
Good News at Fred Hutch
Researchers led by Dr. Ulrike Peters identify six new gene locations for colorectal cancer risk; Drs. Tera Levin and Alistair Russell named Damon Runyon Fellows
Ebola lessons applied to vaccine clinical trials
3 proposals for ‘thinking outside the box’ in public health emergencies
When the doctor is the patient
A kidney transplant and a cancer diagnosis helped shape the career of infection-control expert Steve Pergam
Unraveling the mystery of BV
Scientists in Fredricks' lab detect bacterial species that may cause complications associated with common vaginal infection
HVTN, Merck launch HIV-vaccine trial
'Proof of concept' study involves vaccine candidate designed to generate a cellular immune response that may offer protection against HIV or delay or diminish the course of HIV infection